Literature DB >> 9369473

Active site cavity of herpesvirus proteases revealed by the crystal structure of herpes simplex virus protease/inhibitor complex.

S S Hoog1, W W Smith, X Qiu, C A Janson, B Hellmig, M S McQueney, K O'Donnell, D O'Shannessy, A G DiLella, C Debouck, S S Abdel-Meguid.   

Abstract

Human herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) are responsible for herpes labialis (cold sores) and genital herpes, respectively. They encode a serine protease that is required for viral replication, and represent a viable target for therapeutic intervention. Here, we report the crystal structures of HSV-1 and HSV-2 proteases, the latter in the presence and absence of the covalently bound transition state analog inhibitor diisopropyl phosphate (DIP). The HSV-1 and HSV-2 protease structures show a fold that is neither like chymotrypsin nor like subtilisin, and has been seen only in the recently determined cytomegalovirus (CMV) and varicella-zoster virus (VZV) protease structures. HSV-1 and HSV-2 proteases share high sequence homology and have almost identical three-dimensional structures. However, structural differences are observed with the less homologous CMV protease, offering a structural basis for herpes virus protease ligand specificity. The bound inhibitor identifies the oxyanion hole of these enzymes and defines the active site cavity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9369473     DOI: 10.1021/bi9712697

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  23 in total

1.  Identification and expression of immunogenic proteins of a disease-associated marine turtle herpesvirus.

Authors:  Sadie S Coberley; Richard C Condit; Lawrence H Herbst; Paul A Klein
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

2.  Displacements of prohead protease genes in the late operons of double-stranded-DNA bacteriophages.

Authors:  Jing Liu; Arcady Mushegian
Journal:  J Bacteriol       Date:  2004-07       Impact factor: 3.490

Review 3.  Procapsid assembly, maturation, nuclear exit: dynamic steps in the production of infectious herpesvirions.

Authors:  Giovanni Cardone; J Bernard Heymann; Naiqian Cheng; Benes L Trus; Alasdair C Steven
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

Review 4.  Virus maturation: dynamics and mechanism of a stabilizing structural transition that leads to infectivity.

Authors:  Alasdair C Steven; J Bernard Heymann; Naiqian Cheng; Benes L Trus; James F Conway
Journal:  Curr Opin Struct Biol       Date:  2005-04       Impact factor: 6.809

5.  Cleavage of human cytomegalovirus protease pUL80a at internal and cryptic sites is not essential but enhances infectivity.

Authors:  Amy N Loveland; Chee-Kai Chan; Edward J Brignole; Wade Gibson
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

6.  Substrate modulation of enzyme activity in the herpesvirus protease family.

Authors:  Ana Lazic; David H Goetz; Anson M Nomura; Alan B Marnett; Charles S Craik
Journal:  J Mol Biol       Date:  2007-08-16       Impact factor: 5.469

Review 7.  Overview of protein structural and functional folds.

Authors:  Peter D Sun; Christine E Foster; Jeffrey C Boyington
Journal:  Curr Protoc Protein Sci       Date:  2004-05

Review 8.  Current and potential treatments for ubiquitous but neglected herpesvirus infections.

Authors:  Jonathan E Gable; Timothy M Acker; Charles S Craik
Journal:  Chem Rev       Date:  2014-10-02       Impact factor: 60.622

9.  Inhibition of a viral enzyme by a small-molecule dimer disruptor.

Authors:  Tina Shahian; Gregory M Lee; Ana Lazic; Leggy A Arnold; Priya Velusamy; Christina M Roels; R Kiplin Guy; Charles S Craik
Journal:  Nat Chem Biol       Date:  2009-07-26       Impact factor: 15.040

10.  Communication between the active sites and dimer interface of a herpesvirus protease revealed by a transition-state inhibitor.

Authors:  Alan B Marnett; Anson M Nomura; Nobuhisa Shimba; Paul R Ortiz de Montellano; Charles S Craik
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.